The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba 2+ currents in guinea-pig vascular smooth muscle

British Journal of Pharmacology

Volumn 149, Issue 6, 2006, Pages 786-796

  Zhu, H L ^a   Tomoda, T ^a   Aishima, M ^a   Ito, Y ^a   Teramoto, N ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Antihypertensive drugs; Ca antagonists; Dihydropyridine derivatives; L type Ca 2+ channels; Vascular smooth muscle

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; AMLODIPINE; AZELNIDIPINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL L TYPE; DIHYDROPYRIDINE DERIVATIVE; NIFEDIPINE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GUINEA PIG; MALE; NONHUMAN; PATCH CLAMP; PORTAL VEIN; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE RELAXATION; TENSION; VASCULAR SMOOTH MUSCLE;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ANIMALS; AZETIDINECARBOXYLIC ACID; BARIUM; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; GUINEA PIGS; ION CHANNEL GATING; MALE; MUSCLE, SMOOTH, VASCULAR;

EID: 33751012695     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706919     Document Type: Article

References (25)

1. Alderman MH, Cohen H, Roque R, Madhavan S (1997). Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 349: 594-598.
2. Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I (1999). A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 33: 186-192.
3. Bolton TB, Prestwich SA, Zholos AV, Gordienko DV (1999). Excitation-contraction coupling in gastrointestinal and other smooth muscles. Annu Rev Physiol 61: 85-115.
4. Furberg CD, Psaty BM, Meyer JV (1995). Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circ 92: 1326-1331.
5. 2+ channel agonist Bay K 8644. J Pharmacol Exp Ther 231: 8-15.
6. Koike H, Kimura T, Kawasaki T, Sada T, Ikeda T, Sanbuissho A et al. (2002). Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity. Ann Report Sankyo Res Lab 54: 1-62.
7. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T (2003). Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 26: 201-208.
8. Kuriyama H, Kitamura K, Nabata H (1995). Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Pharmacol Rev 47: 387-573.
9. McFadzean I, Gibson A (2002). The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle. Br J Pharmacol 135: 1-13.
10. Ohya Y, Adachi N, Setoguchi M, Abe I, Fujishima M (1997). Effects of CP-060S on membrane channels in vascular smooth muscle cells from guinea pig. Eur J Pharmacol 330: 93-99.
11. 2+ channel blocker. Jpn J Pharmacol 51: 57-64.
12. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS et al. (1995). The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274: 620-625.
13. Rhodes DG, Sarmiento JG, Herbette LG (1985). Kinetics of binding of membrane-active drugs to receptor sites: diffusion-limited rates for a membrane bilayer approach of 1, 4-dihydropyridine calcium channel antagonists to their active site. Mol Pharmacol 27: 612-623.
14. Romero M, Sanchez I, Pujol MD (2003). New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships. Curr Med Chem Cardiovasc Hematol Agents 1: 113-141.
15. Salvetti A, Di Venanzio L (1994). Clinical pharmacology of long-acting calcium antagonists: what relevance for therapeutic effects? J Cardiovasc Pharmacol 23 (Suppl 5): S31-S34.
16. Shinomiya K, Mizushige K, Fukunaga M, Masugata H, Ohmori K, Kohno M et al. (2004). Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 32: 170-175.
17. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R (1997). Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory blood pressure monitoring and treatment of hypertension investigators. JAMA 278: 1065-1072.
18. 2+ channels. Trends Pharmacol Sci 19: 108-115.
19. Tanaka T, Nangaku M, Miyata T, Inagi R, Ohse T, Ingelfinger JR et al. (2004). Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol 15: 2320-2333.
20. Teramoto N, Brading AF (1996). Activation by levcromakalim and metabolic inhibition of glibenclamide-sensitive K channels in smooth muscle cells of pig proximal urethra. Br J Pharmacol 118: 635-642.
21. Teramoto N, Ogata R, Okabe K, Kameyama A, Kameyama M, Watanabe TX et al. (1996). Effects of calciseptine on unitary barium channel currents in the guinea-pig portal vein. Pflügers Arch 432: 462-470.
22. 2+ channels in smooth muscle cells from pig proximal urethra. Br J Pharmacol 144: 919-925.
23. Thijs L, Den Hond E, Nawrot T, Staessen JA (2004). Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly. Expert Rev Cardiovasc Ther 2: 761-769.
24. Uehara A, Hume JR (1985). Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells. J Gen Physiol 85: 621-647.
25. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T (2004). Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 43: 724-730.